These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 34868001)

  • 1. Kinase Inhibition as Treatment for Acute and Chronic Graft-
    Braun LM; Zeiser R
    Front Immunol; 2021; 12():760199. PubMed ID: 34868001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline
    Uchimura A; Yasuda H; Onagi H; Inano T; Shirane S; Ishii M; Azusawa Y; Hamano Y; Eguchi H; Arai M; Ando J; Ando M
    Heliyon; 2024 Jan; 10(2):e24801. PubMed ID: 38312561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
    Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
    Front Immunol; 2020; 11():593863. PubMed ID: 33324410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
    Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease.
    Palaniyandi S; Strattan E; Kumari R; Mysinger M; Hakim N; Kesler MV; Apatira M; Bittencourt F; Wang L; Jia Z; Gururaja TL; Hill RJ; Hildebrandt GC
    Bone Marrow Transplant; 2023 Aug; 58(8):924-935. PubMed ID: 37160943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
    Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
    Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
    Saidu NEB; Bonini C; Dickinson A; Grce M; Inngjerdingen M; Koehl U; Toubert A; Zeiser R; Galimberti S
    Front Immunol; 2020; 11():578314. PubMed ID: 33162993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells.
    Kondo T; Ikegawa S; Fukumi T; Sumii Y; Sugiura H; Sando Y; Nakamura M; Meguri Y; Iwamoto M; Maeda Y; Matsuoka KI
    Immunohorizons; 2021 Jun; 5(6):424-437. PubMed ID: 34112701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
    De Togni E; Cole O; Abboud R
    Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
    Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
    Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.
    Braun LM; Zeiser R
    Hemasphere; 2021 Jun; 5(6):e581. PubMed ID: 34095764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.